Drug Ming biology and novel coronavirus antibody Vir reach global R & D cooperation

25 novel coronavirus and Biotech Corp Vir Biotechnology (hereinafter referred to as Vir) announced that the two sides reached a cooperation agreement for the development and production of the whole human monoclonal antibody for the treatment of new coronavirus pneumonia (COVID-19) Covid-19 is caused by severe acute respiratory syndrome coronavirus 2 (sars-cov-2) According to the terms of the agreement, the two parties will jointly promote the clinical development, production and commercialization of the leading antibody of vir in the treatment of covid-19 Yao Ming biology will support the development of antibody cell line, technology and preparation, as well as the early production of clinical development Once these antibodies are approved by the regulatory authorities, the company will have the right to commercialize related products in Greater China, and the right to commercialize products in other global markets will be owned by vir VIR has successfully isolated and identified several monoclonal antibodies binding to sars-cov-2 from survivors of SARS infection Further research is underway to determine whether these antibodies or other recognizable antibodies can effectively treat and / or prevent sars-cov-2 "We are very clear about the importance of rapid response in the fight against covid-19," said Dr George A scangos, chief executive officer of vir "If effective antibody therapy can be developed, cooperation with pharmacobiology will maximize the progress of this research and development and overcome this global disease challenge as early as possible." "Yaoming biology and vir agree that it is urgent to promote the clinical application of covid-19 antibody and benefit patients all over the world as soon as possible With the world's leading biomedical development platform and a strong global supply network of biomedical drugs, we will make a unique contribution to accelerating the development and production process of covid-19 antibody therapy, "said Dr Chen Zhisheng, CEO of YaoMing bio." this cooperation once again shows that Yaoming bio is working with global biotechnology companies to accelerate the development process of biomedical drugs and benefit global diseases "Yes."